Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Jun N terminal kinase (JNK) |
Target Info
|
Modulator |
[3] |
| References |
Top |
| REF 1 |
ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
|
| REF 2 |
ClinicalTrials.gov (NCT01466725) A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus. U.S. National Institutes of Health.
|
| REF 3 |
In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
